Trials / Completed
CompletedNCT04649970
Antegrade Double-J Stent Placement for the Treatment of Malignant Obstructive Uropathy
Antegrade Double-J Stent Placement for the Treatment of Malignant Obstructive Uropathy: a Single Center Experience
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 174 (actual)
- Sponsor
- Université de Sousse · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
Ureteral double- J stent is usually inserted by retrograde approach for the treatment of obstructed upper urinary tract. The antegrade approach, can a suitable alternative in certain situations without the need for general or spinal anesthesia. The present study demonstrates the indications, success rate, and complications of this approach in the treatment of malignant obstructive uropathy.
Detailed description
Data of consecutive patients in whom antegrade ureteral stent¬ing was performed between January 2013 and February 2020 were retrospectively analysed using patient records and radiology reports. A total of 174 patients (sexe ratio = 0.51, age range 9-91 years; mean age, 54 years) were included in the study. Ureteral obstruction was caused by bladder cancer (n=92), uterin cancer (n=31), prostate cancer (n=28), colorectal cancer (n= 15) and retroperitoneal tumor (n= 8) (Table 1).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Antegrade double-J stent | After exchanging the nephrostomy catheter over the J-tipped guidewire, 5 F multipurpose (45° tip) diagnostic vascular catheter was inserted. Once the pelvi¬ureteric junction was crossed and the ureter accessed, a straight hydrophilic guidewire and a catheter were used. Then, the cath-eter was advanced into the bladder over the wire, this guidewire was exchanged for an ultra-stiff guidewire, an 8 or 10 F double J ureteral stent was placed over the guidewire, and the safety kit of the stent was removed. A final fluoroscopic image was stored for correcting the stent position. |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2017-06-29
- Completion
- 2020-02-02
- First posted
- 2020-12-02
- Last updated
- 2020-12-04
Source: ClinicalTrials.gov record NCT04649970. Inclusion in this directory is not an endorsement.